Floatz logo

Zonisamide

Migraine Disorder

Kafrelsheikh UniversitySmall moleculePhase 4 / ApprovedActive
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
73/ 100

Competitive context

100 Active assets in the Migraine Disorder cohort.

Asset / SponsorPhaseRating
Atogepant
Stanford University
Phase 4A
Rizatriptan
Antonios Likourezos
Phase 4A
Zolmitriptan
Zosano Pharma Corporation
Phase 4A
Naproxen
IRCCS San Raffaele Roma
Phase 4A
Ubrogepant
H. Lundbeck A/S
Phase 4BBB

View all 50 →

Same molecule, other indications

Zonisamide is also rated in:

focal epilepsyActive
BBB
Indicative · Phase 4
74 / 100
View asset →
epilepsyActive
BB
Indicative · Phase 4
69 / 100
View asset →
epilepsy with generalized tonic-clonic seizuresActive
B
Indicative · Phase 4
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →